Attorney General Misses Deadline for Easier Schedule I Research Rules

Attorney General Pam Bondi has missed a critical January deadline to simplify the path for scientists studying Schedule I substances like cannabis and psychedelics. Even though President Trump signed the HALT Fentanyl Act last year—which included provisions to cut through the DEA's red tape for researchers—the necessary guidelines from the AG’s office are nowhere to be found. Advocates from groups like Students for Sensible Drug Policy are sounding the alarm, noting that this delay stalls medical breakthroughs and keeps potential treatments for mental health and addiction out of reach.

For everyday tokers, this administrative foot-dragging is more than just a missed date; it’s a roadblock to progress. We all want the science to back up what the community already knows, and easier research access is the only way to get legitimate, evidence-based data into the hands of policymakers. Until Bondi acts, the "research harm" continues, leaving both scientists and patients in a frustrating state of limbo. It’s high time the government follows its own rules so the industry can finally move forward with clarity.